Kailera Therapeutics (KLRA) director details large option grant

Rhea-AI Filing Summary

Kailera Therapeutics director Martin Mackay filed an initial ownership report showing a stock option position rather than a new share purchase or sale. The option covers 170,194 shares of Common Stock with an exercise price of $11.56 per share and expires on March 10, 2036.

According to the vesting terms, 25% of the total shares vest on March 10, 2027, with the remaining options vesting in 36 substantially equal monthly installments, contingent on his continued service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MACKAY MARTIN

Role null

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 170,194 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Underlying option shares: 170,194 shares Exercise price: $11.56 per share Option expiration: March 10, 2036 +2 more

5 metrics

Underlying option shares 170,194 shares Common Stock underlying reported stock option holding

Exercise price $11.56 per share Strike price of Stock Option (right to buy)

Option expiration March 10, 2036 Expiration date of the stock option award

Initial vesting milestone 25% on March 10, 2027 First vesting tranche of the stock option

Subsequent vesting period 36 monthly installments Remaining vesting schedule after March 10, 2027

Key Terms

Stock Option (right to buy), underlying security, exercise price, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

underlying security financial

"underlying_security_title: "Common Stock""

exercise price financial

"conversion_or_exercise_price: "11.5600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-03-10T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The options vest and become exercisable as to 25% of the total shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MACKAY MARTIN

(Last) (First) (Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/16/2026

3. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	03/10/2036	Common Stock	170,194	$11.56	D

Explanation of Responses:

1. The options vest and become exercisable as to 25% of the total shares on March 10, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ John Mei, Attorney-in-fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Martin Mackay’s Form 3 filing for Kailera Therapeutics (KLRA) report?

The Form 3 reports Martin Mackay’s initial ownership of a stock option on Kailera Therapeutics shares. It discloses a right to buy 170,194 shares of Common Stock, providing a baseline view of his equity-linked position as a director.

How many Kailera Therapeutics (KLRA) shares are covered by Martin Mackay’s option?

The reported stock option is exercisable for 170,194 shares of Kailera Therapeutics Common Stock. This figure reflects the total underlying shares tied to the option award, offering insight into the scale of his potential equity exposure if the option fully vests and is exercised.

What is the exercise price and expiration date of Martin Mackay’s KLRA stock option?

The stock option has an exercise price of $11.56 per share and an expiration date of March 10, 2036. These terms define the cost to acquire each share and the final date by which the option must be exercised before it lapses.

How does the vesting schedule work for Martin Mackay’s Kailera Therapeutics option?

The option vests 25% of the total shares on March 10, 2027, then in 36 substantially equal monthly installments. Vesting is conditioned on his continued service, so each future vesting date requires him to remain with the company for additional portions to become exercisable.

Does Martin Mackay’s Form 3 show any recent buying or selling of KLRA shares?

The Form 3 does not show recent buying or selling activity. It records a stock option holding with no reported purchase or sale transactions, serving as an initial disclosure of his derivative equity position rather than a record of market trades in Kailera Therapeutics shares.